Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by BidaskClub

BidaskClub upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) from a sell rating to a hold rating in a research note released on Wednesday, BidAskClub reports.

A number of other analysts have also weighed in on the company. HC Wainwright initiated coverage on Zentalis Pharmaceuticals in a report on Thursday, August 27th. They set a buy rating and a $43.00 target price for the company. Cantor Fitzgerald initiated coverage on Zentalis Pharmaceuticals in a report on Monday, September 28th. They set an overweight rating and a $44.00 target price for the company. Morgan Stanley upped their target price on Zentalis Pharmaceuticals from $45.00 to $49.00 and gave the stock an overweight rating in a report on Monday, August 24th. SVB Leerink restated a buy rating on shares of Zentalis Pharmaceuticals in a report on Tuesday, July 28th. Finally, Zacks Investment Research upgraded Zentalis Pharmaceuticals from a sell rating to a hold rating in a report on Saturday, July 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $44.86.

Shares of NASDAQ ZNTL opened at $42.00 on Wednesday. The company has a 50 day moving average price of $32.02. Zentalis Pharmaceuticals has a 52-week low of $22.00 and a 52-week high of $59.32.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.28). As a group, research analysts expect that Zentalis Pharmaceuticals will post -4.69 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer.

Featured Article: Why is momentum important to successful trading?

Analyst Recommendations for Zentalis Pharmaceuticals (NASDAQ:ZNTL)

Receive News & Ratings for Zentalis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zentalis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.